Not a member? Register now and gain FREE access to over 100 private,
pre-IPO, IPO and Small Cap ASX Listed opportunities!

Wholesale Investor is a FREE service for high net worth, professional and international investors. Registration takes less than 30 second and gives you:

Email Or Login with your Please wait...

Archive: Biomedical / Biotechnology

arthritis 75x55

Arthritis Relief Plus Annual Update 2016; US FDA Compliance Completed, Australian Government Support & First Commercial Batch in US

Arthritis Relief Plus Ltd (ARP) attained countless achievements during 2016. The company managed to complete US FDA compliance, securing an OTC topical drug status/ classification for 4Jointz. With also securing Australian Government support in the first cohort at the Rocketspace … Continue reading

Proteo-logo-HR-80x80

Proteomics International Raises $1.44 Placement and Now Offering a Share Purchase Plan

2nd December 2016, ASX Announcement Proteomics International is a specialist innovation-driven medical technology company based in Perth, Western Australia. Focused on the area of proteomics- the industrial scale study of the structure and functions of proteins. Established in 2001, providing services … Continue reading

Proteo-logo-HR-80x80

Proteomics International (ASX: PIQ) Diabetic Kidney Disease Test Granted Patent in Russia

19th December 2016 – ASX Announcement Medtech company Proteomics International Laboratories (PILL) has been granted a patent in the Russian Federation for the company’s breakthrough diagnostic and prognostic test for diabetic kidney disease, “PromarkerD”. By country, the Russian Federation has … Continue reading

Actinogen Logo Square

Significant Advance in Development of Actinogen’s Alzheimer’s Drug

19th December 2016 – ASX Announcement Xanamem™ human research data accepted for publication in major medical journal Xanamem™ specifically designed to inhibit excess cortisol production in the brain Excess cortisol in the brain associated with Alzheimer’s disease Xanamem™ being trialled … Continue reading

UBI 800x800

Universal Biosenors Acquires Hemostasis Reference Laboratory

19th December 2016 – ASX Announcement Universal Biosensors Inc (ASX: UBI) has announced that its wholly-owned Canadian operating subsidiary has signed an agreement with LifeLabs LP (LifeLabs) to acquire the assets of LifeLabs’ Hemostasis Reference Laboratory business (HRL) in preparation … Continue reading

PILL logo HR

Proteomics Share Purchase Plan Offer Document

7th December 2016 – ASX Announcement  Proteomics International Laboratories Ltd (ASX:PIQ) (the Company, PILL) is pleased to present to you the opportunity to apply to increase your investment in the Company through an offer of shares under the Company’s Share … Continue reading

Actinogen Logo Square

Actinogen Medical Present Xanamem Research at CTAD

6th December 2016, ASX Announcement Actinogen Medical Limited (ASX:ACW) is pleased to announce the presentation of the latest Xanamem™ research data at CTAD (Clinical Trials in Alzheimer’s Disease) in San Diego. The paper: Xanamem™: an 11ß-HSD1 Inhibitor in current development … Continue reading

PILL logo HR

Proteomics Completes $1.44 million Placement and Offers SPP

2nd December 2016, ASX Announcement Medtech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is pleased to announce it has completed the first phase of a targeted capital raising by placement of 6m shares at $0.24 to raise $1.44m (the … Continue reading

Actinogen Logo Square

Actinogen Medical Annual General Meeting & Presentation

30th November 2016, ASX Announcement Progress with the development of Xanamem Since addressing you at the AGM this time last year, Actinogen has made substantial progress towards the initiation of XanADu, our Phase II study of Xanamem in mild Alzheimer’s … Continue reading

suda80x80

SUDA Ltd Audio Webcast

1st December 2016 SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, provides the opportunity to listen to an audio broadcast with Mr Stephen Carter, SUDA’s Managing Director & CEO, in a presentation titled: SUDA Ltd and Eddingpharm Enter … Continue reading

oncosil80x80

OncoSil Pancreatic Cancer Clinical Study Update

28th November 2016, ASX Announcement OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to provide an update on its global OncoPaC … Continue reading

Antisense-Logo-email

Antisense Therapeutics Ltd (ASX: ANP)

Antisense Therapeutics Ltd (ASX: ANP) is an Australian publicly traded biopharmaceutical development company. Continue reading

IMU-HR-LOGO-01

Imugene Ltd (ASX: IMU)

Imugene is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Continue reading

suda80x80

SUDA Presents Data On Novel Penetration-Enhancing Technology

17th November 2016 SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announced that Mr. Stephen Carter, Managing Director and CEO, presented data on the Company’s novel penetration-enhancing technology at the Annual Symposium of Drug Delivery Systems, being … Continue reading

Proteo-logo-HR-80x80

Proteomics and Linear Partner in Testing and Clinical Trials

15th November 2016, ASX Announcement Medical technology company Proteomics International Laboratories Ltd (ASX: PIQ) (PILL) and clinical trial specialists Linear Clinical Research Ltd (Linear) are set to offer a combined advanced analytical testing and clinical trial package from January 2017. … Continue reading

Proteo-logo-HR-80x80

Proteomics PromarkerD Test Kit Production Deal Signed

11th November 2016, ASX Announcement Medtech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) today reached a strategic milestone in its commercialisation pathway for PromarkerD, the company’s predictive test for diabetic kidney disease. PILL signs production contract with Monash Antibody … Continue reading

suda80x80

SUDA Enters Licensing Agreement For ZolpiMist in China

9th November 2016, ASX Announcement SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, and Eddingpharm (Asia) Macao Commercial Offshore Limited (Eddingpharm), a leading Chinese pharmaceutical company, today announce that the companies have entered into an exclusive license agreement … Continue reading

suda80x80

SUDA Files Patent Application For Novel Mucosal Penetration Technology

2 November 2016, ASX Announcment SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announced that it has filed a provisional patent application with IP Australia for a novel mucosal penetration drug delivery technology. The application was filed … Continue reading

suda80x80

SUDA Appendix 4C For First Quarter FY2017

31 October 2016, ASX Announcement SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the first quarter of FY2017. Receipts from customers for the period were $1.6 million, an … Continue reading

Proteo-logo-HR-80x80

Proteomics Wins WA Exporter of the Year

31st October 2016, ASX Announcement Medical technology company Proteomics International Laboratories Ltd (ASX: PIQ) has edged out shipbuilding giant Austal and Fortescue Metals Group to win the WA Exporter of the Year Award. The company also took out the Health … Continue reading

Actinogen-Logo-Square2-80x80

Actinogen Medical Annual Report to Shareholders 2016

24th October 2016, ASX Announcement Chaimans Address It is a great pleasure on behalf of the Board to present the 2016 Actinogen Medical Annual Report. This year’s many achievements are the result of careful and prudent long-term strategic planning and … Continue reading

Proteo-logo-HR-80x80

Proteomics Targets Gastro-Causing Parasite

20th October 2016, ASX Announcement Perth life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) has successfully applied its biomarker discovery platform Promarker to the parasite Giardia. PILL maps samples from the gastro-causing parasite Giardia. Giardiasis is one of … Continue reading

oncosil80x80

OncoSil Medical CEO Presentation & AGM October 2016

18th October 2016, ASX Announcement Achievements Delivered FY16 September 2015 – Submission of CE Mark application for OncoSil™ October 2015 - OncoSil™ CE Mark application granted Fast Track review status December 2015 – Investigational Device Exemption submitted to the FDA for … Continue reading

Proteo-logo-HR-80x80

Proteomics Appoints New Non-Executive Director

14th October 2016, ASX Announcement Life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is delighted to announce the appointment of Mr Roger Moore as a Non-Executive Director of the Company. The appointment brings key industry and sector experience … Continue reading

Actinogen-Logo-Square2-80x80

Actinogen Medical Investor Research Update

September 27, 2016 Actinogen Medical (ASX:ACW) met again with Baker Young Stockbrokers to discuss Xanamem™’s past research and recent initiation of XanADu, a Phase II clinical trial in Alzheimer’s disease (AD). Best Risk vs Reward Play in Alzheimer’s Dementia Baker Young maintains coverage of Actinogen Medical with a BUY recommendation and value … Continue reading

UBI 800x800

Universal Biosensors Welcomes FDA Clearance for Xprecia Stride Analyzer

5th October 2016, ASX Announcement Universal Biosensors (ASX: UBI) today welcomes news that the US Food and Drug Administration (FDA) has cleared for sale in the US the Xprecia Stride Coagulation Analyzer which is produced by partner Siemens Healthineers and uses … Continue reading

Proteo-logo-HR-80x80

SA Capital Initiates Proteomics Research Report

4th October 2016, ASX Announcement Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is pleased to advise that SA Capital has initiated coverage on PILL. BUSINESS MODEL Proteomics International Laboratories Ltd (PILL) operates in three integrated areas unified by its proprietary … Continue reading

2-OPAL_Biosciences_Logo-psd (1)

Opal Biosciences Annual Report 2016

Hard-to-treat infections that used to be rare are now more common. Because of advances in medical management of cancers, HIV, cystic fibrosis and organ transplants, as examples, there is a larger pool of people with weakened immune systems or having … Continue reading

Actinogen-Logo-Square2-80x80

FDA Feedback on Actinogen’s Xanamem Alzheimer’s Trail

29th September 2016, ASX Announcement Actinogen Medical Limited (ASX: ACW) advises that it has received feedback from the FDA today with further questions around potential safety surveillance of the drug Xanamem to be answered before patients can be treated in the … Continue reading

UBI 800x800

Universal Biosensors Receives $9.36m Under the R&D Tax Incentive

30th September 2016, ASX Announcement Universal Biosensors (ASX:UBI) today announced it has received $9.36M in cash  under the R&D Tax Incentive for the 2015 financial year noting it had recorded a receivable of $9.20M in its financial statements. The R&D … Continue reading

oncosil80x80

OncoSil Receives $2.3m R&D Tax Incentive Refund

26th September 2016, ASX Announcement OncoSil Medical Limited (ASX:OSL) (OncoSil Medical or the Company) a late stage medical company focused on localised treatments for subjects with pancreatic and liver cancer, is pleased to announce it has received a cash refund … Continue reading

suda80x80

SUDA Annual Report to Shareholders 2016

22nd September 2016, ASX Announcement Letter From The Chairman  “Our global reputation in oro-mucosal drug delivery is growing as we continue to generate new discussion with potential partners as well as progressing existing discussions along the project cycle.” Looking at … Continue reading

Proteo-logo-HR-80x80

Proteomics International Receives FY16 R&D Tax Incentive

21st September 2016, ASX Announcement Innovative biomarker research conducted by Proteomics International Laboratories Ltd (PILL, ASX: PIQ) has been boosted by the receipt of more than half a million dollars in research and development tax incentive for the 2015-16 financial … Continue reading

Actinogen Logo Square

Actinogen Medical CEO Interview

Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease. Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. … Continue reading

Suda-logo-3-80x80

SUDA Investor Road Show Presentation September 2016

20th September 2016, ASX Announcement a leader in oro-mucosal drug delivery, today announces that Mr. Stephen Carter, Managing Director and CEO, and Mr. Nick Woolf, Chief Business Officer, are meeting with investors, brokers and analysts in Brisbane, Sydney and Melbourne … Continue reading

biodiem 80x80

BioDiem Annual Report & Notice of Meeting 2016

NOTICE OF GENERAL MEETING  Notice is given that the Annual General Meeting of Members of BioDiem Limited (“BioDiem” or the “Company”) will be held at the offices of Grant Thornton, Wills Room, The Rialto, Level 30, 525 Collins Street, Melbourne … Continue reading

Actinogen-Logo-Square2-80x80

Actinogen Medical’s Understanding Alzheimer’s Event

Actinogen Medical looks forward to seeing you at our “Understanding Alzheimer’s” Symposium in Melbourne this Wednesday! Don’t forget to RSVP to reserve your spot, if you haven’t done so already – we’re sure it will be a meaningful event. The Brains … Continue reading

Suda-logo-3-80x80

SUDA Letter to Shareholders September 2016

13th September 2016, ASX Announcement SUDA Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, today published its sixth shareholder newsletter, which will be mailed to shareholders. Mr Stephen Carter, Chief Executive Officer of SUDA said: “The newsletter is a valuable … Continue reading

oncosil80x80

OncoSil Medical Annual Report 2016

12th September 2016, ASX Announcement FY16 Achievements Delivered September 2015  Submission of CE Mark application for OncoSil™ October 2015 OncoSil™ CE Mark application granted Fast Track review status December 2015 Investigational Device Exemption (IDE) submitted to the U.S. FDA for OncoPac-1 … Continue reading

Actinogen Logo Square

Actinogen Invitation: Understanding Alzheimer’s Event

The Brains Behind Saving Yours Alzheimer’s disease is one of the greatest health issues of our time. Join us on World Alzheimer’s Day to hear from leading experts in Alzheimer’s research and individuals experienced in coping with the burden of … Continue reading

Proteo-logo-HR-80x80

Proteomics Investigates Biomarkers for Mesothelioma

6th September 2016, ASX Announcement PILL commences the search for protein biomarkers in the blood that could be used to diagnose mesothelioma. World Health Organisation estimates put the cost of treatment, compensation and settlement upwards of AU$667,00 for every sufferer.  Mesothelioma … Continue reading

Actinogen Logo Square

Actinogen Medical Receives R&D Tax Incentive

5th September 2016, ASX Announcement Actinogen Medical Limited (ASX: ACW) is pleased to advise that the Company has received an R&D Tax Incentive rebate of $2,784,312 for the 2015/2016 financial year. The R&D Tax Incentive is an Australian Government program … Continue reading

Actinogen Logo Square

Actinogen Medical’s Progress with Alzheimer’s Trial

1st September 2016, Actinogen It’s been some months since our last update on Actinogen Medical and the development program for Xanamem™. Over this time we’ve made significant progress in harmonisation of the Phase II XanADu protocol and we have every expectation that all approvals for the … Continue reading

suda80x80

Consistent Revenue for SUDA

The revenue is consistent with the prior year and was generated by Suda Ltd’s subsidiary company Westcoast Surgical and Medical Supplies Pty Ltd. Whilst maintaining revenue, the Group has reduced operating costs resulting in a decrease in the loss attributable … Continue reading

oncosil80x801

OncoSil Financial Report – Preliminary Final Report; $10m Private Placement; Advanced Manufacturing and Supply Chain Processes

30th August 2016, ASX Announcement OncoSil Medical Ltd (ASX:OSL) (Oncosil or the Company), a late stage medical devices company focused on localised treatments with pancreatic and liver cancer, is pleased to report its financial results to the full year ended … Continue reading

Proteo-logo-HR-80x80

Proteomics Annual Report to Shareholders 2016

26th August 2016, ASX Announcement Window On The Science – Proteins in medicine  A revolution in medicine is well underway, underpinned by the desire for a deeper understanding of the basis of disease beyond that of classical pathology. Determining what … Continue reading

Proteo-logo-HR-80x80

Proteomics International Expands Diagnostics Portfolio to Endometriosis

24th August 2016, ASX Announcement Life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is applying its disruptive proteomics technology platform to new areas of significant unmet medical need. PILL is investigating protein ‘fingerprints’ that can diagnose endometriosis from … Continue reading

oncosil80x801

Oncosil Medical Investor Presentation August 2016

22nd August 2016, ASX Announcement Overview Developing an implantable radiotherapy medical device ‘OncosilTM’ for pancreatic and liver cancer CE Mark targeted in the near term followed by commercial launch and sales in UK, EU and Australia Technology platform suitable for … Continue reading

oncosil80x80

Hot Calibration Run of the OncoSil Device

18th August 2016, ASX Announcement OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company), a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that it has successfully … Continue reading

Proteo-logo-HR-80x80

Proteomics Secures First Commercialisation Deal for PromarkerD

18th August 2016, ASX Announcement Life sciences company Proteomics International Laboratories  (ASX: PIQ) (PILL) has signed an exclusive license for its PromarkerD assay for the diagnosis of diabetic kidney disease in the Dominican Republic in Central America. Highlights: Diabetic kidney … Continue reading

Actinogen Logo Square

Actinogen Receives Offer to Purchase All Less Than Marketable Parcels of Shares

16th August 2016, ASX Announcement The Board of Actinogen Medical Limited (ASX: ACW) (Actinogen or the Company) is pleased to announce that it has received an offer from an Australian financial services licensee to purchase all less than marketable parcels … Continue reading

atomo 800x800

Bill Gates Backs Aussie Biotech Start-Up Atomo Diagnostics

11th August 2016, Sydney Morning Herald By Brian Robins In a rare public display of support for Australian technology, a large US investment fund backed by Microsoft founder Bill Gates has taken a stake in a local biotech start-up. Launched in 2010 and … Continue reading

biodiem 80x80

BioDiem Complete Successful Entitlement Offer

9th August 2016, BioDiem BioDiem advises that it has now successfully completed the issue and allotment of entitlement and shortfall convertible preference shares under the shortfall facility of its recent Non-Renounceable pro-rata Entitlement Offer. Funds will be used to progress the … Continue reading

prescient

Prescient Therapeutics Granted USPTO Allowances for Two PTX-200 Patents

4th August 2016, ASX Announcement Clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) is pleased that the US Patent and Trademark Office (USPTO) has issued two notices of allowance under the PTX-200 patent families “Effective treatment of tumors and cancer with … Continue reading

oncosil80x80

OncoSil Medical Receives IDE Approval from the U.S. FDA

2nd August 2016, ASX Announcement OncoSil Medical Limited  (ASX: OSL) (OncoSil Medical or the Company) a late stage medical devices company focused on localised treatments for subjects with pancreatic and liver cancer, is pleased to announce that it has recieved … Continue reading

dimerix

Dimerix FY16 Update: Significant Progress on its DMX-200 Program, FDA Confirmation, Trial Recruiting Well

Dimerix has made significant progress on its DMX-200 program for chronic kidney disease. Dimerix met with the US Food and Drug Administration (FDA) discussing DMX-200 development for Focal Segmental Glomerularsclerosis (FSGS). Dimerix confirmed the DMX-200 regulatory path as an adjunct … Continue reading

Suda-logo-3-80x80

SUDA Quarter Update June 2016: Cash Position at $2.4 million

29th July 201 SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the fourth quarter of FY2016. Receipts from customers for the period were $1.5 million, an increase of … Continue reading

UBI 800x800

Universal Biosensors FY16 Update: Net Profit Reported, Valuable Partnerships with Siemens and Johnson & Johnson

UBI has undergone an exciting period of change over the past 12 months. UBI reported strong first half results with Quarterly Service Fee revenues from the market leading OneTouch® Verio blood glucose strip product up 58%. In addition, operating expenses … Continue reading

unknown1

Sementis Ltd

Sementis Limited aims to become a global leader in the development and commercialisation of vaccines targeted at the treatment or prevention of allergies. Continue reading

Actinogen Logo Square

Actinogen Medical Announces Landmark Research on Excess Cortisol and Alzheimer’s Disease

28th July 2016, ASX Announcement Australian CSIRO and university funded AIBL study links excess cortisol and Alzheimer’s disease. Anti-Alzheimer’s compound Xanamem™ in clinical testing blocks high cortisol (“stress” hormone) associated with disease progression. Landmark research on disease mechanism and Actinogen … Continue reading

Proteo-logo-HR-80x80

Proteomics International Quarterly Report June 2016: Cash Flow Strengthened & Cash Burn Reduced

28th June 2016, ASX Announcement Life sciences comp-any Proteomics International Laboratories Ltd (ASX: PIQ) )the Company, PILL), is pleased to provide the following update on its business activities for the three month period to 30 June 2016. Building on previous … Continue reading

biodiem 80x80

BioDiem FY16 Update: Nasovac-S Export Approved, Clinical Trials Due to Finish FY17, New Formulations Planned

BioDiem’s focus is the prevention and treatment of infectious diseases. Royalties flow to BioDiem from sales of Nasovac-S™ in India, a flu vaccine manufactured by Serum Institute of India (SII) under licence from BioDiem. In FY16, after achieving approval to … Continue reading

biodiem 80x80

BioDiem Entitlement Offer Closes Friday July 29th

BioDiem’s pro rata nonrenounceable Entitlement Offer to raise up to $1,250,000 (before costs) is closing soon. Funds will be used to progress the next phase of commercialization of BioDiem’s influenza vaccine (LAIV) licensing business; and its antimicrobial, BDM-I, in development for … Continue reading

oncosil80x80

OncoSil Medical Quarterly Activities & Cash Flow Report June 2016

27th July 2016, ASX Announcement OncoSil Medical Ltd (ASX: OSL) (Oncosil of the Company), a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer today released its Appendix 4C – Quarterly Cashflow report … Continue reading

UBI 800x800

Universal Biosensors H1 2016 Results, Presentation and Audio Presentation

21st July 2016, ASX Announcement Highlights: Total revenue of $10.5 million in 1H16, up 41% on1H15 Revenue from Quarterly Service Fees – generated by sales of glucose test strips – $10.3 million, up 58% on 1H15 Net loss of $1.2 … Continue reading

Actinogen Logo Square

Actinogen has US Patent Granted and Further Extends Xanamem Protection

20th July 2016, ASX Announcement United States Patent granted for use of Xanamem™ in Alzheimer’s dementia and other diseases. Xanamem™’s long patent life now further extended to 2031 in the US. Comprehensive protection over Xanamem™ now received for most major markets. … Continue reading

biodiem 80x80

BioDiem Non-Renounceable Pro-rata Entitlement Offer Closes July 29th

15th July 2016 BioDiem’s pro rata nonrenounceable Entitlement Offer to raise up to $1,250,000 (before costs) is closing soon. Funds will be used to progress the next phase of commercialization of BioDiem’s influenza vaccine (LAIV) licensing business; and its antimicrobial, BDM-I, … Continue reading

Actinogen Logo Square

Actinogen Medical US Roadshow Investor Presentation July 2016

15th July 2016, ASX Announcement Focusing on an innovative approach, through the inhibition of cortisol production, for treating cognitive impairment in chronic neurodegenerative and metabolic diseases Xanamem™:  A prime investment opportunity  Alzheimer’s – a significant unmet need in a huge … Continue reading

UBI 800x800

Universal Biosensors 1H 2016 Financial Results Webcast

13th July 2016, ASX Announcement Universal Biosensors (ASX:UBI) will be hosting an investor webcast to discuss the 2016 Half Year Financial Results on Thursday, 21 July 12.00pm noon AEST. The call will be hosted by Universal Biosensors Executive Chairman Andrew … Continue reading

bioactive-80x50

Bioactive Laboratories FY16 Update – Welcomes New Investors, Kicks Off New Drug Development Project & Celebrates TGA Milestone

Bioactive Laboratories welcomes its new investors & continues to invite SMSF investors to its register. The Drug Development Division is powering ahead with the New Molecule Discovery project at the Eskitis Institute. The significance of this project, in creating a … Continue reading

bioactive 80x50

VIDEO: Bioactive Laboratories Latest Investor Presentation at WI Investor Evening June 2016

Please watch Bioactive Laboratories Founder and MD, Rick Ferdinands, present at the WI Investor Evening June 2016. ABOUT BIOACTIVE LABORATORIES  Bioactive Laboratories specialises in plant based enhanced extracts. They have developed an anti-microbial that is potent to one of the … Continue reading

Actinogen Logo Square

Actinogen Medical Receive Positive Results from Phase I Study & Begin Phase II Study

Actinogen Medical is focused on the treatment of Alzheimer’s disease. The lead drug candidate Xanamem™, blocks the production of excess cortisol (the stress hormone), which is associated with cognitive impairment and the development of amyloid plaques and neurodegeration in the … Continue reading

oncosil80x80

OncoSil Medical to Attend 48th European Pancreatic Club Meeting

6th July 2017, ASX Announcement OncoSil Medical Limited (ASX:OSL) (OncoSil Medical or the Company) a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, today announced that a team of senior management would … Continue reading

Suda-logo-3-80x80

SUDA FY16 Update; Several Patents Granted Internationally, Strong IP Portfolio, Operation and Staff Expansion

SUDA LTD made steady progress with its pipeline of OroMist® oral sprays in FY2016. This included finalising the design of a pivotal PK trial and meeting with the FDA regarding the Company’s SUD-001 sumatriptan oral spray for the treatment of … Continue reading

UBI 800x800

Universal Biosensors Appoints Craig Coleman as Non-Executive Director

30th June 2016, ASX Announcement Universal Biosensors, Inc (ASX: UBI) today announced the appointment of Mr. Craig Coleman as a non-executive director to the Board of Universal Biosensors. This appointment continues the board renewal process which has occurred over recent … Continue reading

oncosil80x80

OncoSil Medical Regulatory Update June 2016

30th June 2016, ASX Announcement OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company) a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to provide an update on its … Continue reading

Actinogen Logo Square

Actinogens’ Xanamem™ to Showcase Cortisol Hypothesis

29th Sydney 2016, ASX Announcement Actinogen Medical (ASX:ACW) is pleased to announce the key data supporting its novel Alzheimer’s drug Xanamem™, has been selected by an independent expert panel for presentation at the world’s largest dementia research conference – the Alzheimer’s Association … Continue reading

Proteo-logo-HR-80x80

Proteomics International Laboratories Board Changes

28th June 2016, ASX Announcement Proteomics International Laboratories Ltd (ASX: PIQ) (the Company) announces that Dr Bill Parker and Mr James Moses have resigned as Directors of the Company. Dr Parker was a founder of Proteomics International in 2001, and … Continue reading

UBI 800x800

Universal Biosensors Business Update; Fast Revenue Growth, Unique Patent Protected Technology & New Product Development

21st June 2016, ASX Announcement UBI: Investment Highlights: Targeting the large and growing Point-of-Care Diagnostics market Fast growth in revenues based on sale of disposable test strips Validating the technology through partnering deals with LifeScan and Siemens Unique patent protected … Continue reading

Screen-shot-2014-06-25-at-3.19.19-PM1

Bioactive Laboratories Pty Ltd

Bioactive Laboratories specialises in unique and patented plant based health solutions Continue reading

biodiem 80x80

BioDiem Non-Renounceable Pro-Rata Entitlement Offer

14th June 2016, BioDiem BioDiem announces a pro rata nonrenounceable Entitlement Offer to raise up to approximately $1,250,000 (before costs). Funds will be used to progress the next phase of commercialization of BioDiem’s influenza vaccine (LAIV) licensing business; and its … Continue reading

suda80x80

SUDA Announces New Analyst Report

14th June 2016, ASX Announcement SUDA LTD (ASX: SUD), a leader in oro-mucosal drug deliver, today announces that Alpha Deal Group, LLC has issued a new investment report on SUDA. The reports from Alpha Deal Group were commissioned by SUDA … Continue reading

Proteo-logo-HR-80x80

Proteomics PromarkerD Development Advances in China

14th June 2016, ASX Announcement Highlights: PILL and its Chinese partner Newsummit Biopharma have secured funding towards development for an In vitro Diagnostic (IVD) kit for PromarkerD in China. Chinese patent granted for PromarkerD as a predictive and diagnostic test … Continue reading

Actinogen Logo Square

Actinogen Receives US FDA Feedback to Enhance Alzheimers Study

8th June 2016, ASX Announcement Highlights: Productive interaction with the US Food and Drug Administration (FDA) Protocol enhancement will strengthen the value of the Phase II trial Harmonising Australian and UK trial with US FDA increases potential global value Fits … Continue reading

suda80x80

SUDA June 2016 Investor Update; Negotiations to Licence Oro-Muscal Sprays Continue, Expansion of Business Development in China, ChinaBio Conference

7th June 2016, ASX Announcement SUDA Ltd (ASX: SUD), a leader in oro-muscal drug delivery, notes the weakness in its share price and today provides an update on its activities. Negotiations with pharmaceutical companies to licence SUDA’s first-in-class oro-muscal sprays … Continue reading

suda80x80

SUDA Update on HC Berlin Pharma

3rd June 2016, ASX Announcement SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has received a Statement of Claim in relation to a lawsuit between the Company and HC Berlin Pharma AG (in liquidation). … Continue reading

atomo 800x800

John Kelly, Atomo Diagnostics’ Founder and CEO Interviewed on Switzer TV

25th May 2016, Swtizter Atomo Diagnostics is making waves in the diagnostics technology space, and has even attracted the support of the Bill and Melinda Gates Foundation. To look at the company’s innovations, CEO John Kelly joins the show (broadcast … Continue reading

atomo 800x800

Innovative New Rapid Blood Test to Tackle Tropical Diseases from Atomo Diagnostics

30th May 2016, Atomo Diagnostics Award-winning designer and manufacturer of diagnostic medical devices, Atomo Diagnostics today announced that it has been successful in securing $1.38 million in grant funding from the Australian Government to assist in the development and commercialisation … Continue reading

atomo 800x800

Gates Foundation’s Global Health Chief Joins Atomo Diagnostics

28th May 2016, The Australian By Sarah-Jane Tasker The top lieutenant at the Bill & Melinda Gates Foundation’s ­global health fund is joining the board of Australia’s Atomo Diagnostics after the fund took an ­equity position in the medical ­device … Continue reading

Proteo-logo-HR-80x80

Proteomics Gaining Strong Traction in Analytical Services

20th May 2016, ASX Announcement PILL has generated monthly revenues of $100,000 in each of March and April (a 60% uplift on the previous monthly average). Several recent contract wins underscore ongoing activity. Growth driven by biosimilars (generic protein drug) … Continue reading

prescient

Prescient Therapeutics Secures $7.0M Capital Raising

18th May 2016, ASX Announcement $7.0 M institutional placement Rights issue on same terms to raise up to a further $3.4 M Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to advise the successful completion of … Continue reading

oncosil80x80

OncoSil Appoints Michael Warrener as Global Sales and Marketing Director

18th May 2016, ASX Announcement OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company) is pleased to announce the appointment of Mr Michael Warrener as Global Sales and Marketing Director. Mr Warrener will be responsible for implementing the Company’s … Continue reading

Arthritis-Plus-Logo3

Arthritis Relief Plus Ltd

ARP has developed and patented a novel technology – Acteev® with its lead product – 4Jointz®, a topical botanical cream addressing a significant unmet market need. It is commercial ready for key international markets. Continue reading

UBI 800x800

Universal Biosensors Annual Report 2016

May 12th, ASX Announcement Chairman’s Letter  “Our company is a proud developer of medical diagnostic systems that make a difference to people’s lives around the world every day. Through our efforts, the technology we have developed with our partners is … Continue reading

oncosil80x80

OncoSil Medical Presents at Asia BiotechInvest

4th May 2016, ASX Announcement OncoDil Medical Limied (ASX: OSL) (OncoSil Medical or the Company) a late stage medical devices company focused on localised treatments for patients with pancreatic cancer and liver cancer, today announced that Chief Executive Officer, Daniel … Continue reading

suda80x80

SUDA Investor Presentation May 2016

3rd May 2016, ASX Announcement Overview  SUDA (ASX: SUD) is a drug delivery company commercialising low-risk pharmaceuticals Extensive proprietary technology, expertise and knowhow in formulating and manufacturing oral sprays Multiple patent families covering approx. 300 widely-used drugs formulated into oral … Continue reading

suda80x80 (1)

SUDA Reports 3Q Increase in Receipts & Positive Net Operating Cash Flow

29th April 2016, ASX Announcement SUDA LTD (ASX:SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the third quarter of FY2016. Receipts from customers for the period were $1.6 million, an increase … Continue reading

PILL logo HR

Proteomics March Update: PromarkerD Progress, Indian Biotech Market Expansion & Solid Quarter Results

26th April 2016, ASX Announcement Life sciences company Proteomics International Laboratories Ltd (ASX:PIQ) (the Company, PILL)  is pleased to provide the following update on its business activities for the three month period to 31 March 2016. Highlights  PromarkerD progress: 500 … Continue reading

UBI 800x800

Universal Biosensors Q1 2016 Results; Total Revenue Up 64%

21st April 2016, ASX Announcement Universal Biosensors (ASX: UBI) today released its financial results for the first quarter of 2016. When comparing the Q1 2016 results with Q1 2015: Net loss is down 42% Total revenue is up 64% to … Continue reading

suda80x80

SUDA Update: Funding for Second Phase III Study of ArTiMist™, BIO-Europe Spring International Partnering Conference & More

19th Apriul 2016, ASX Announcement SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces an update on its business development activities. The Company is in advanced negotiations with multiple pharmaceutical companies regarding licensing its first-in-class oral sprays … Continue reading

PILL logo HR

Proteomics to Expand Operations in Indian Market

14th April 2016, ASX Announcement Highlights: PILL to expand to Indian biotech sector – rapidly growing global biotech hub forecast to be worth $US100b by 2025. PILL to conduct India trade visit this month to drive uptake to biosimilars analytics … Continue reading

Actinogen-Logo-2

Actinogen Medical Ltd (ASX: ACW)

Actinogen Medical Limited (ASX:ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease. Continue reading

prescient

Prescient Therapeutics Investor Presentation April 2016

13th April 2016, ASX Announcement Investment Summary: Why all the excitement about AML? Acute Myeloid Leukemia (AML) is an area of substantial unmet medical need. – One of the worst survival rates of all cancers – Standard of care unchanged … Continue reading

suda80x80

SUDA Granted Canadian Patent for SUD-002

12th April 2016, ASX Announcement SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug deliver, is pleased to announce that the Canadian Intellectual Property Office has issued Canada Patent number 2,673,049, covering the Company’s novel oral spray of ondansetron (SUD-002). … Continue reading

UBI 800x800

Universal Biosensors Product Update

1st April 2016, ASX Announcement Universal Biosenors (ASX:UBI) provides below an update to its product development pipeline. The company has been conducting a review of its current development projects with a view to prioritising development spend and focusing on projects … Continue reading

biodiem 80x80

BioDiem Commence Influenza Vaccine Clinical Trial in China

31st March 2016, BioDiem Changchun BCHT Biotechnology Co (BCHT) has made rapid progress in the development of its ‘flu vaccine in China since licensing the LAIV technology from BioDiem just three years ago. During this time, BCHT has developed the manufacturing … Continue reading

oncosil80x80

OncoSil Medical Investor Presentation March 2016

23rd March 2016, ASX Announcement OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to release its latest Investor Presentation, delivered at Bell Potter Securities Limited’s Emerging Leaders Day in Sydney. The Presentation provides an overview and update … Continue reading

PILL logo HR

Proteomics Commences Therapeutic Drug Discovery Program

23rd Marc h 2016, ASX Announcement Highlights:  PILL to utilise its proprietary disruptive technology platform to assess potential new painkilling and antibiotic drug compounds. Therapeutic Drug Discovery is one of PILL’s core business areas and is a major growth market … Continue reading

UBI 800x800

Universal Biosensors Shareholder Newsletter; Financial Results, R&D Developments, & OneTouch Verio Flex™

In this edition we hear from Universal Biosensors’ new non-executive director, David Hoey, look at what R&D means for UBI, hear about LifeScan’s latest innovation with its OneTouch Verio Flex device, and farewell CEO Paul Wright. FROM THE CEO’S DESK … Continue reading

biodiem 80x80

Congratulations BioDiem, Making it into The Top 25 R&D Spin-Offs List

13th March 2016, Science Meets Business For a country that makes up just 0.3% of the world’s population, Australia packs a heavyweight punch in science – generating 3.9% of the world’s research publications. However taking that research to market has proved … Continue reading

UBI 800x800

Modifications to Collaboration Arrangements with Universal Biosensors and Siemens

9th March 2016, ASX Announcement Universal Biosensors (ASX: UBI) announced today that it has agreed amendments to its agreements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide  prepayment … Continue reading

Proteo-logo-HR-80x80

Proteomics PromarkerD Update

7th March 2016, ASX Announcement Highlights: Follow up, validation study on 500 patient cohort underway – results to be announced in due course. Company is instigating its own development program to produce a standard clinical pathology In vitro Diagnostic (IVD) … Continue reading

prescient

Edison Investment Research Initiates Coverage on Prescient Therapeutics

3rd March 2016, ASX Announcement Edision Investment Research Limited has initiated coverage of clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX). The full report can be found under the Media/Press & Research Reports tab on the Company’s website www.prescienttherapeutics.com or found … Continue reading

Unity.Pacific.Sig.Logo

Universal Biosensors Appoints David Hoey as Non-Executive Director

2nd March 2016, ASX Announcement Universal Biosensors, Inc. (ASX: UBI) today announced the appointment of Mr. David Hoey as an independent non-executive director to the Board of Universal Biosensors (UBI). This appointment forms part of the board renewal process which … Continue reading

prescient

Prescient Featured on Bloomberg’s – The Redchip Money Report

2nd March 2016, ASX Announcement The new CEO of clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX), Steven Yatomi-Clarke, will appear on Bloomberg Network’s The Red Chip Money Report later this week. Mr Yatomi-Clarke’s interview with host Dave Gentry will … Continue reading

oncosil80x80

OncoSil Market Update; Commercialisation, Clinical and Corporate Highlights

1st March 2016, ASX Announcement OncoSil Medical Limited (ASX: OSL) OncoSil Medical or the Company) provides the following update on its activities since the Quarterly Announcement on 28 January 2016. Commercialisation  The Company continues to be in active engagement with … Continue reading

suda80x80

SUDA Releases Half Yearly Report; Acquisition of Subsidiary Company, Suda Europe Ltd Established & New Patent

26th February 2016, ASX Announcement SUDA Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4D for the consolidated Group for the half year ended 31 December 2015. Key events during the reporting period included: i. The … Continue reading

biodiem 80x80

BioDiem and Opal Biosciences Presentation from the Life Science & Healthcare Showcase

26th February 2016, BioDiem BioDiem’s CEO, Julie Phillips presented at the Wholesale Investor Life Science & Healthcare Showcase, held at ASX Offices, Exchange Centre in Sydney on 25th February 2016. The event targeted investors and included life science and healthcare companies. The BioDiem/Opal presentation focused … Continue reading

Proteo-logo-HR-80x80

Proteomics International Laboratories Interim Financial Report

26th February 2016, ASX Announcement Proteomics International Laboratories Limited (PILL) is a life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteings. The Company’s business model operates from a … Continue reading

suda80x80

SUDA Investor Presentation

25th February 2016, ASX Announcement Overview SUDA (ASX: SUD) is a drug delivery company commercialising low-risk pharmaceuticals Extensive proprietary technology, expertise and knowhow in formulating and manufacturing oral sprays Multiple patent families covering approx. 300 widely-used drugs formulated into oral … Continue reading

UBI-800x8001-80x80

Universal Biosensors Announces Retirement of CEO Paul Wright

19th February 2016, ASX Announcement Mr. Wright announced today his decision to retire as Chief Executive Officer of Universal Biosensors, Inc. (ASX:UBI) and to resign from the Company’s Board of Directors, with effect from 10 March 2016. Mr. Wright noted … Continue reading

UBI-800x8001-80x80

Universal Biosensors Announces FY2015 Results Showing Strong Revenue Growth and Positive Operating Cash

17th February 2016, ASX Announcement Highlight of FY 2015 Revenue from Quarterly Service Fees – generated by sales of OneTouch Verio blood glucose test strips by LifeScan – up 99% to $12.8 million in FY 2015 from $6.4 million in … Continue reading

biodiem 80x80

BioDiem Investor Briefing: Life Science and Healthcare Showcase February

17th February 2016 BioDiem’s CEO, Julie Phillips will be presenting at the Wholesale Investor Life Science and Healthcare Showcase, held at ASX Offices, Exchange Centre in Sydney on Thursday, 25 February 2016. The BioDiem/Opal presentation is focused on BioDiem’s revenue-generating … Continue reading

prescient

Prescient Therapeutics PTX-200 Breast Cancer Trial Progresses

17th February 2016, ASX announcement PTX-200 Breast Cancer Trial Progress Phase Ib breast cancer trial enters expansion cohort H.Lee Moffitt Cancer Center joins trial recruitment Melbourne, Australia 17 February 2016: Clinical stage oncology company Prescient Therapeutics Ltd (PTX) is pleased … Continue reading

prescient

Prescient Therapeutics Appoints Steven Yatomi-Clarke as CEO

15th February 2016, ASX Announcement Clinical stage oncology company, Prescient Therapeutics Ltd (PTX) is pleased to advise that it has appointed Steven Yatomi-Clarke as Chief Executive Officer and Managing Director of the Company. Steven has a distinguished career in the … Continue reading

suda80x80

SUDA featured in Business Review Australia

11th February 2016, issuu Business Review Australia by Eric Harding. Having established a broad technology platform for its oromucosal drug OroMist, SUDA Ltd is now constructing a pharmaceutical business based on reformulated products that demonstrate major cost, functional and effectual … Continue reading

atomo 800x800

The Medtech Hub Down Under

9th February 2016, MDDI Online  By Marie Thibault Australia has an outsized reputation for exotic flora, cute koalas, and awe-inspiring beaches, but it is also a bright star in the medical technology industry. The country actually outpaces the United States … Continue reading

suda80x80

SUDA Ltd Announces New Analyst Coverage

9th February 2016, ASX Announcement SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that Alpha Deal Group, LLC has initiated coverage of SUDA. The initiation report, which was commissioned by SUDA, is available on the Company’s … Continue reading

Proteo-logo-HR-80x80

Proteomics Launch New Company Website and Corporate Video

9th February 2016, ASX Announcement Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce the launch of its new company website. The website is available at: www.proteomics.com.au or www.proteomicsinternational.com.au The new website replaces the previous … Continue reading

suda80x80

SUDA Shareholder Update; Negotiations with Licensing Partners & €6m Grant Application

8th February 2016, ASX Announcement SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces an update to shareholders describing the Company’s progress towards its business development goals and advancement of its pipeline of first- in-class oral sprays. … Continue reading

suda80x80

SUDA Receives $0.7m R&D Tax Incentive Refund

5th February 2016, ASX Announcement SUDA Ltd (AX: SUD), a leader in oro-mucosal drug delivery, today announces that it has received a refund of $0.7 million from the Australian Taxation Office under the the R&D Tax Incentive for eligible expenditure … Continue reading

OncoSil_Logo_4c

$10 Million Institutional Placement to Drive OncoSil Commercialisation

3rd February 2016, ASX Announcement OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce a A$10 million Institutional Placement (Placement) to drive commercialisation of the Company’s lead product candidate, the OncoSilTM localised radiation treatment for cancer. … Continue reading

biodiem 80x80

BioDiem Raises Over $580K

Entitlement Offer and Placement raises $589,793 BioDiem Limited (“BioDiem” or “the Company”) advises that it has now completed the issue and allotment of entitlement and shortfall shares under the shortfall facility of its recent Non-Renounceable Entitlement Offer. Read more. Appointment of Professor … Continue reading

prescient

Prescient Therapeutics Quarter Summary and Key Activities

25th January 2016, ASX Announcement Prescient Therapeutics Limited (“Prescient” or “the Company”) provides the following Appendix 4C in relation to the quarter ended 31 December 2015. In January 2016, the Company carried out investor roadshows in the US meeting key … Continue reading

Proteo-logo-HR-80x80

Big Achievements for Proteomics in December Quarter 2015 – Full Report Available

21st January 2016, ASX Announcement Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to provide the following update on its business activities for the three month period from 31 December 2015. Highlights: PromarkerD Commercialisation … Continue reading

prescient

Prescient Therapeutics Presents at NobleCon12

21st January 2016, ASX Announcement  Clinical stage oncology company Prescient Therapeutics Limited (ASX:PTX), today announced that Director, Mr Steven Yatomi-Clarke, has presented at the NonbleCon12 – Noble Financial Capital Markets’ Twelfth Annual Investor Conference at Club Med in Sandiper Bay, … Continue reading

OncoSil_Logo_4c

OncoSil Appoints Independent Non-Executive Director

21st January 2016, ASX Announcement OncoSil Medical Limited (ASX: OSL) is pleased to announce the appointment today of Dr Chris Roberts as an Independent Non-Executive Director of the Company, with immediate effect. Dr Robert is a highly experienced director and senior … Continue reading

atomo 800x800

Atomo Secures US$6M from the Global Health Investment Fund

January 13, 2016 The investment will support scale up of Atomo’s global health activities, focusing on continued rollout of its award winning AtomoRapid™ HIV test and launch of an affordable HIV self-test offering unmatched performance The Global Health Investment Fund … Continue reading

atomo 800x800

Desmond Tutu HIV Foundation Successfully Complete Study on Atomo HIV Self Test

Cape Town, South Africa The Desmond Tutu HIV Foundation has successfully completed an acceptability and usability study on HIV self-testing using the Atomo HIV Self Test. With 224 participants enrolled, the study provides valuable information into one potential avenue to … Continue reading

prescient

Yale Hematolgy Leader Joins Prescient Therapeutics Scientific Advisory Board

14th January 2016, ASX Announcement Clinical stage oncology company Prescient Therapeutics Ltd (PTX) has appointed a highly respected US-based specialist in myeloid malignancies Dr Thomas Prebet MD, PhD of Yale Cancer Center to the PTX Scientific Advisory Board (SAB). Dr … Continue reading

atomo 800x800

Atomo Diagnostics Secures US$6M from Global Health Investment Fund Backed by Bill Gates

14th January 2016, Sydney Morning Herald by John McDuling An investment fund backed by billionaire Bill Gates is pouring $6 million into a Sydney HIV and malaria testing company. The US based Global Health Investment Fund (GHIF), which was set … Continue reading

prescient

Prescient Therapeutics to Present at Biotech Showcase 2016 in San Francisco

11th January 2016, ASX Announcement Clinical stage oncology company, Prescient Therapeutics Ltd (ASX:PTX) advises that it will be presenting at the Annual Biotech Showcase is San Francisco, USA this week. Biotech Showcase is a respected investor and networking conference devoted … Continue reading

prescient

FDA Allows Prescient IND for Leukemia Phase Ib & II Trials

8th January 2016, ASX Announcement Highlights: PTX has four FDA approved INDs demonstrating the strength of its cancer treatment assets Follows Phase I study that demonstrated 17 out of 32 patients achieved disease stabilization. These were patients with advanced leukemia … Continue reading

biodiem 80x80

BioDiem Fund-Raising Update January 2016

Announcement: BioDiem Fund-raising update placement to two major shareholders in September 2015 ($298,820) rights issue and additional commitment from major shareholders ($289,373)  R&D Tax Incentive rebate received $215,707 Licence fee for LAIV received US$84,197 Shortfall available for allocation: $158K,025 (1,975,316 shares) To … Continue reading

OncoSil_Logo_4c

Oncosil Medical Group (ASX:OSL) Annual Update 2015; Shares Up Over 182%

2015 Highlights: Share price up 182.35% Completed the granted Fast Track review by the European regulator Conformité Européenne International life sciences research group, Van Leeuwenhoeck Institute, initiated an analyst research coverage on the Company Multiple new Board Appointments ABOUT ONCOSIL … Continue reading

dimerix

Dimerix Annual Update 2015; Lists on the ASX & Commences Phase II Clinical Study

Dimerix Bioscience has made substantial progress in a number of corporate and operational areas in 2015. In July, Dimerix Bioscience was acquired by Sun Biomedical (who subsequently changed its name to Dimerix Limited ASX:DXB). On 17th December, Dimerix announced the … Continue reading

UBI 800x800

Universal Biosensors (ASX: UBI) Annual Update 2015; Share Price up 159% & Revenues up 160%

Universal Biosensors has seen its share price more than double over the year, up from 17.6c on January 5 to 44.5c on December 14 – an increase of 159%. The company’s financial performance has also been strong, with total revenues … Continue reading

UBI 800x800

Universal Biosensors Investor Newsletter December 2015

As we approach Christmas and the holiday season, we look back at what’s been an eventful year for Universal Biosensors. The year is also ending on a high for innovative companies like UBI with the release of the Federal Government’s … Continue reading

opal

Opal Biosciences Annual Update 2015; Granted New Patents

Opal Biosciences, an innovative player in infectious disease treatment, achieved key milestones in 2015 with its lead “super bug” fighting technology BDM-I. Work started on development of an injectable formulation by a specialist group in the UK. This will enable … Continue reading

bioactive 80x50

Bioactive Laboratories – On Target For a US Launch Within 24 Months

Enormous growth has occurred in 2015. Bioactive has brought forward its drug development pipeline by two years after significant infectious disease discoveries were confirmed by the Walter and Eliza Hall Institute of Medical Research. Collaboration and the formation of a … Continue reading